References
1. Okamoto, T., Nagaya, K., Sugiyama, T., Aoyama, A., Nii, M., & Azuma,
H. (2021). Two patients of trisomy 21 with transient abnormal
myelopoiesis with hypereosinophilia without blasts in peripheral blood
smears. Pediatric hematology and oncology , 38 (2),
168–173. https://doi.org/10.1080/08880018.2020.1826070
2. Yamato, G., Park, M. J., Sotomatsu, M., Kaburagi, T., Maruyama, K.,
Kobayashi, T., Nishi, A., Sameshima, K., Ohki, K., & Hayashi, Y.
(2021). Clinical features of 35 Down syndrome patients with transient
abnormal myelopoiesis at a single institution. International
journal of hematology , 113 (5), 662–667.
https://doi.org/10.1007/s12185-020-03066-7
3. Manohar, S., & Jayakumar, N. (2022). ”TAM”ing of the
shrew-challenges in the diagnosis of Neonatal leukemia with Down’s
syndrome -A case report with literature review. Indian journal of
pathology & microbiology , 65 (3), 699–701.
https://doi.org/10.4103/ijpm.ijpm_731_21
4. Al-Kershi, S., Golnik, R., Flasinski, M., Waack, K., Rasche, M.,
Creutzig, U., Dworzak, M., Reinhardt, D., & Klusmann, J. H. (2021).
Recommendations for Diagnosis and Treatment of Children with Transient
Abnormal Myelopoiesis (TAM) and Myeloid Leukemia in Down Syndrome
(ML-DS). Empfehlungen für die Diagnose und Behandlung von Kindern mit
transienter abnormer Myelopoese (TAM) und myeloischer Leukämie bei Down
Syndrom (ML-DS). Klinische Padiatrie , 233 (6), 267–277.
https://doi.org/10.1055/a-1532-2016
5. Hayasaka, I., Cho, K., Morioka, K., Kaneshi, Y., Akimoto, T., Furuse,
Y., Moriichi, A., Iguchi, A., Cho, Y., Minakami, H., & Ariga, T.
(2015). Exchange transfusion in patients with Down syndrome and severe
transient leukemia. Pediatrics international: official journal of
the Japan Pediatric Society , 57 (4), 620–625.
https://doi.org/10.1111/ped.12586
6. Park, E. S., Kim, S. Y., Yeom, J. S., Lim, J. Y., Park, C. H., &
Youn, H. S. (2008). Extreme thrombocytosis associated with transient
myeloproliferative disorder with Down Syndrome with t(11;17)(q13;q21).Pediatric blood & cancer , 50 (3), 643–644.
https://doi.org/10.1002/pbc.21029
7. Kosmidou, A., Tragiannidis, A., & Gavriilaki, E. (2023). Myeloid
Leukemia of Down Syndrome. Cancers , 15 (13), 3265.
https://doi.org/10.3390/cancers15133265
8. Yuzawa, K., Terui, K., Toki, T., Kanezaki, R., Kobayashi, A., Sato,
T., Kamio, T., Kudo, K., Sasaki, S., Endo, M., Ozono, S., Nomura, K., &
Ito, E. (2020). Clinical, cytogenetic, and molecular analyses of 17
neonates with transient abnormal myelopoiesis and nonconstitutional
trisomy 21. Pediatric blood & cancer , 67 (4), e28188.
https://doi.org/10.1002/pbc.28188
9. Grimm, J., Heckl, D., & Klusmann, J. H. (2021). Molecular Mechanisms
of the Genetic Predisposition to Acute Megakaryoblastic Leukemia in
Infants With Down Syndrome. Frontiers in oncology , 11 ,
636633. https://doi.org/10.3389/fonc.2021.636633
10. Bhatnagar, N., Nizery, L., Tunstall, O. et al. Transient
Abnormal Myelopoiesis and AML in Down Syndrome: an Update. Curr
Hematol Malig Rep 11 , 333–341 (2016).
https://doi-org.evms.idm.oclc.org/10.1007/s11899-016-0338-x
11. Crispino, J. D., & Horwitz, M. S. (2017). GATA factor mutations in
hematologic disease. Blood , 129 (15), 2103–2110.
https://doi.org/10.1182/blood-2016-09-687889
12. Massey, G. V., Zipursky, A., Chang, M. N., Doyle, J. J., Nasim, S.,
Taub, J. W., Ravindranath, Y., Dahl, G., Weinstein, H. J., & Children’s
Oncology Group (COG) (2006). A prospective study of the natural history
of transient leukemia (TL) in neonates with Down syndrome (DS):
Children’s Oncology Group (COG) study POG-9481. Blood ,107 (12), 4606–4613.
https://doi.org/10.1182/blood-2005-06-2448
13. Walter, R.B., Appelbaum, F.R. & Estey, E.H. Optimal dosing of
cytarabine in induction and post-remission therapy of acute myeloid
leukemia. Leukemia 35, 295–298 (2021).
https://doi-org.evms.idm.oclc.org/10.1038/s41375-020-01110-3
14. Lee, J. W., Kim, S., Jang, P. S., Chung, N. G., Cho, B., & Kim, M.
(2021). Marked thrombocytosis resulting in pseudohyperkalemia in a
neonate with transient abnormal myelopoiesis. Pediatric blood &
cancer , 68 (8), e28986. https://doi.org/10.1002/pbc.28986